Prevalence of VKORC1 Polymorphism in Population of Hyderabad India

Primary tabs

Acta Medica International,2015,2,2,108-111.
Published:July 2015
Type:Original Article

Prevalence of VKORC1 Polymorphism in Population of Hyderabad India

Amrita Rao1, Gita Sharma2, Livy Alex3, R Tapadia4

1Research Associate, Tapadia Diagnostic Centre Pvt Ltd, Hyderabad,

2R&D Director, Tapadia Diagnostic Centre Pvt Ltd, Hyderabad,

3Director, Tapadia Diagnostic Centre Pvt Ltd, Hyderabad, 4Director Technical, SLS Cell Cure Technologies Pvt Ltd, Hyderabad


Introduction: Warfarin/Acitrom administration dosage varies based on patient genotype with respect to the gene: Vitamin K epoxide reductase complex 1 (VKORC1). Ethnic diversity contributes to genotype variation. The frequency of polymorphism at VKORC1 in population of Hyderabad has not been reported in literature; hence the present study was conducted. Material & Methods: Genomic DNA from peripheral blood leukocytes of patients on warfarin/acitrom as well as normal control population without any thrombotic disease was extracted and Restriction Fragment Length Polymorphism (RFLP) pattern was established for 1173C>T transition by standard protocols. Result: The incidence of homozygote dominants (CC) genotypes were 74.63% and that of heterozygotes (CT)
were 25.37 %. No recessives were found in the study group. Conclusion: Presently genotype based dosage is not implemented. This study through its collaboration with practising cardiologist while establishing the test at our diagnostic centre has also enabled awareness and consequently if followed will improve patient safety.

Genotyping of VKORC1 1173. a) Agarose gel showing genomic DNA (lane 1) and molecular size marker of 1 kb (lane M). b) Agarose gel showing PCR product of size 361 bp (lane 2) and DNA Ladder molecular size marker of 50bp (lane M of b &c). c) Agarose gel showing Hinf1 digestion of PCR products. Lane 3 represents CT with 353bp and 310bp and Lane 4 represents CC with 353bp.